Inovio Pharmaceuticals Class Action Lawsuit
Analysis based on 9 articles · First reported Feb 12, 2026 · Last updated Mar 09, 2026
The market is negatively impacted for Inovio Pharmaceuticals, Inc. as its stock price fell significantly due to the United States===Food and Drug Administration's decision and the subsequent class action lawsuit. This event highlights regulatory risks in the pharmaceutical industry.
Inovio Pharmaceuticals, Inc. is facing a class action lawsuit for allegedly making false and misleading statements to investors between October 10, 2023, and December 26, 2025. The lawsuit claims that Inovio Pharmaceuticals, Inc. misrepresented the manufacturing quality of its CELLECTRA device, the timeline for submitting its INO-3107 Biologics License Application (BLA) to the United States===Food and Drug Administration (FDA), and the eligibility of INO-3107 for accelerated approval or priority review. On December 29, 2025, the United States===Food and Drug Administration announced it accepted Inovio Pharmaceuticals, Inc.'s BLA for INO-3107 on a standard review timeline, not accelerated approval, leading to a 24.45% drop in Inovio Pharmaceuticals, Inc.'s stock price. The Portnoy Law Firm is advising investors and pursuing claims.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard